LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 23
- 试验地点
- 4
- 主要终点
- Analysis of the effectiveness of Ellaone. This will be assessed by the production of RNA PMP22 using skin biopsy.
研究概览
简要总结
The disease Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited peripheral neuropathy, for which no treatment has proved its effectiveness. It is autosomal dominant, associated with a duplication of the chromosome 17p11.2 region which leads to overexpression of the gene and the protein-peripheral myelin protein-22 (PMP22), a major component of peripheral myelin.
In animals and humans, PMP22 mRNA level of glutathione S-transferase theta 2 and Cathepsin A (markers of oxidative stress), detected in a skin biopsy are markers that may play a role in the prognosis evolution of the disease. Furthermore, several studies have shown that the administration of progesterone increased the expression of PMP22 gene (measured in a skin biopsy) and worsening symptoms. In contrast, anti-progestins reduce the synthesis of PMP22 and improve symptoms in rat CMT1A.
The long-term safety of anti-progesterone was evaluated for mifepristone (RU486) ulipristal acetate and (EllaOne®). Few side effects have been reported including a few cases of endometrial hyperplasia reversible upon discontinuation of treatment. With the RU486, rare cases of adrenal androgen and failure have been observed. However, EllaOne® has low antagonistic action on the glucocorticoid receptor and no action on androgen receptors. The investigators therefore believe that it will be well tolerated in humans and will reduce the synthesis of PMP22 and the action of oxidative stress by improving disability of patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male 18-70 years
- •CMT1A proven genetically (17p11.2 duplication)
- •symptomatic CMT1A (MRC score <5 in at least one muscle group)
- •Non severe axonal impairment (amplitude of the motor evoked potential on the median nerve and / or ulnar than 50% of normal)
- •Subject contacted with a valid phone number
- •Subject affiliated to a social security scheme
- •Subject has been informed of the results of the medical examination prior
排除标准
- •Another cause of neuropathy: Chronic alcohol intoxication, chemotherapy, diabetes, kidney failure, monoclonal gammopathy, cryoglobulin, B12 deficiency, hepatitis B / C, HIV, Lyme or poliomyelitis
- •Liver failure
- •Lapp lactase deficiency, malabsoprtion syndrome glucose / galactose
- •Support long-term drug interacting with the CYP3A4
- •Patients with indication against xylocaine adrenaline
- •In the biopsy site: surgery, skin disease or local infection
- •Immunosuppression innate or acquired
- •Hypersensitivity to the active substance / excipient
- •uncontrolled severe asthma
- •Treatment with vitamin C or vitamin B3 in the four weeks preceding randomization
- •Orthopaedic surgery of the lower limbs in the 6 months prior to randomization or planned
- •Against indication xylocaine adrenaline
- •Malfunction of the innate or acquired coagulation
研究组 & 干预措施
1
Arm (1) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne (Drug)
1
Arm (1) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne placebo (Drug)
2
Arm (2) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne (Drug)
2
Arm (2) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne placebo (Drug)
3
Arm (3) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne (Drug)
3
Arm (3) will be randomised to receive either :
- 5 mg/per os of EllaOne every day through 12 months.
- 10 mg/per os of EllaOne every day through 12 months.
- EllaOne placebo/per os every day through 12 months.
干预措施: EllaOne placebo (Drug)
结局指标
主要结局
Analysis of the effectiveness of Ellaone. This will be assessed by the production of RNA PMP22 using skin biopsy.
时间窗: 12 months after treatment with EllaOne
次要结局
未报告次要终点